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gression analysis are the number of days of heparin use
and the intensity of diagnostic follow-up, as expressed by
the number of VQ-scans. CONCLUSIONS: The manage-
ment of PE, from suspicion until discharge, is rather con-
sistent; however, large inter-individual variation in hospital
stay is observed. Interestingly, the length of hospitaliza-
tion is related to the duration of heparin use. This perhaps
opens perspectives for anticoagulation that can be ad-
ministered ambulatory. A patient chart review has the
advantage over database research that only resource use
strictly related to the investigated condition can be identified.
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OBJECTIVE: To determine pharmacoeconomically opti-
mal hypolipidemic drug for preventive maintenance of
CAD in women of elder age groups. METHODS: 110
women, average age 59  3,4 yrs., with menopause du-
ration more than 5 years, hypercholesterolemia types IIA
and IIB, coronary heart disease, angina pectoris of II–III
functional class without clinical signs of heart insuffi-
ciency were included into the study. They were divided
into 5 groups by a method of envelopes: patients of I
group received simvastatinin - 10–20 mg o.d., patients of
II group - fluvastatin 40–80 mg o.d., patients of III group -
pravastatin 20–40 mg o.d., IV group - fenofibrate 200
mg o.d., V group-ciprofibrate - 100 mg o.d. Statins were
initially given in bioequivalent doses. The groups of ther-
apy were completely comparable to age; duration of dis-
ease and character of accompanying therapy, and also by
levels TC and LDL-C Therapy duration was 12 weeks.
After 4 and 12 weeks the levels of TC, LDL-C, HDL-C,
TG and also conventional biochemical criterion of safety
of therapy were determined. The criterion of cost-effec-
tiveness for each drug was defined under the following
formula, permitting to determine the cost of 1% reduc-
tion of LDL-C by various hypolipidemic drugs: Ñ-E 
(DMC  FC)/% of LDL-C reduction, where DMC—the
direct medical costs including cost of a medical reception
and cost of an out-patient inspection according to the
standards of the prices for medical services in adult out-
patient departments of Moscow under the program of
voluntary medical insurance in 1997–98; FC-cost of a
monthly course of treatment by different drugs in Mos-
cow chemist’s web in 1997–98. CONCLUSION: The
comparison of hypolipidemic drugs by a criterion “cost-
effectiveness”, using as a criterion of therapy efficiency
percentage of LDL-C reduction, arranged the drugs as
follows: ciprofibrate (100 mg) - fluvastatin (40 mg) - sim-
vastatin (10 mg) - fenofibrate (200mg) - fluvastatin (80mg) -
simvastatin (20mg) - pravastatin (20 mg) - pravastatin
(40 mg).
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OBJECTIVE: To examine the variation in total costs of
treating patients with hypercholesterolemia to achieve
EAS LDL-C target concentration levels using statins.
METHODS: A randomized, 54-week, controlled trial
was conducted to compare resources used when treating
patients to EAS LDL-C targets using atorvastatin, fluva-
statin, pravastatin and simvastatin. Variation in total
costs among the arms of the study could be attributed to
the time at which patients achieved LDL-C targets and
the services and medications required to reach LDL-C
target. Costs include costs of study drug, add-on therapy,
physician office visits, lab tests and attributable adverse
events. RESULTS: There was substantial variation in to-
tal costs and in the components of total costs among
study arms. Patients treated with atorvastatin achieved
LDL-C target significantly faster (P  0.05) at lower
doses of study drug and required significantly fewer clinic
visits than patients treated with comparator statins. Con-
sequently, mean total cost of care to reach LDL-C targets
were significantly lower than costs for patients treated
with comparators (P  0.05). CONCLUSION: Costs for
treating patients to LDL-C targets with HMG-CoA re-
ductase inhibitors varied significantly among drugs. To-
tal costs of therapy were lowest with atorvastatin, when
compared to other reductase inhibitors examined in this
study.
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OBJECTIVE: To examine the variation in total costs of
treating patients according to EAS LDL-C target concen-
tration levels attributable to use of alternative HMG-
CoA reductase inhibitors (statins). METHODS: A ran-
domized, 54-week, controlled trial was conducted to
compare resources used when treating patients to EAS
LDL-C targets using atorvastatin, fluvastatin, pravastatin
and simvastatin. The trial enrolled 336 patients. Patients
were dispensed study drugs according to the protocol;
starting at the lowest dose and titrating up at regular in-
tervals if LDL-C targets were not met. Per the protocol,
the amount of resources consumed varied based upon the
time at which patients achieved LDL-C targets. In this
treat-to-target study, it was possible to achieve target in
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as few as 3 visits or to never achieve target and undergo
10 visits. Total costs include costs of study drug, add-on
therapy, physician office visits, lab tests and attributable
adverse events. Costs for physician office visits in Spain
(GP) were 1 327 pts and costs for lipid panels were 4 090
pts. RESULTS: Patients treated with atorvastatin achieved
LDL-C target significantly faster (P  0.05) at lower
doses of study drug and required significantly fewer clinic
visits than patients treated with comparator statins. Con-
sequently, mean total cost of care to reach LDL-C targets
were significantly lower than costs for patients treated
with comparators (P  0.05). CONCLUSION: Costs for
treating patients to LDL-C targets with HMG-CoA re-
ductase inhibitors varied significantly among drugs. To-
tal costs of therapy in Spain were lowest with atorvastatin,
when compared to other reductase inhibitors examined
in this study.
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OBJECTIVES: The purpose of this study is to determine
the annual economic burden of stroke, given that cere-
brovascular disease is one of the leading causes of death
and disability in Greece. METHODS: Retrospective da-
tabase selection was made regarding patients with stroke,
hospitalized in Greek hospitals. We modeled the disease
based on the existing epidemiological, demographic, clin-
ical and economic data in order to estimate direct and in-
direct cost by stroke type, degree of severity, age group
and deaths. Clinical data derive from National Statistical
Service of Greece. Incidence and prevalence data are
based on Greek experts’ published reports. Inpatient
care unit costs, sickness funds payments, patient’s out-of-
pocket money and any other expenses are based on prices
set by the Ministry of Labour. Cost analysis is based on
one-year patient treatment and survival. RESULTS: An-
nual direct cost per patient is $6,700 including hospital-
pharmaceutical care, laboratory-diagnostic tests, outpa-
tient’s visits and rehabilitation. Percentage distribution is
45% hospital care, 30% rehabilitation, 10% diagnostic
tests, 9% pharmaceutical care and 6% consultation. The
annual burden to the sickness funds is estimated at
$7,000 per severe event and $2,000 per moderate event.
Losses from the societal perspective are estimated at
$25,700 for the severe and $6,300 for the moderate
event. CONCLUSIONS: Annual direct cost of stroke is
estimated at $170 million in Greece. Sickness funds cost
is $20,7 million while the societal burden is much higher
at $58,3 million due to chronic residual disabilities.
Given the considerable societal and economic impact of
stroke in Greece, enormous clinical and economic bene-
fits could be achieved through the expansion of second-
ary prevention, the adoption of economic evaluation
analyses regarding the various interventions and drug
therapies and finally through the creation of specialized
stroke units, non-existent in our country.
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OBJECTIVE: The GREAT (GRoup on Economic As-
sessment of hyperTension) study has the objective to esti-
mate the cost of care of hypertension study in Emilia Ro-
magna region and to evaluate the degree of blood pressure
(BP) control. METHODS: Twenty-seven GPs and 9 spe-
cialists centres participated in a previously reported
cross-sectional part of the study. Nine GPs and 2 special-
ists centres completed the longitudinal section of the
study. Demographic, clinical and economic information
was collected. Health care provided to patients has been
quantified in the perspective of the Italian National
Health Service (NHS), by means of tariffs. We report on
health care costs evaluated in the longitudinal section of
the study. All costs are presented as monthly costs and
expressed in Euros (1€  1936.27 ITL). RESULTS: 106
patients were assessed in the longitudinal study, 46
women (mean age 63  12) and 60 men (63  10). The
average follow-up period was 202  68 days and there
was one death. Fifty-eight (55%) patients had comorbid-
ities, 13 (12%) were smokers. The mean levels of SBP
and DBP were 138  35 and 81  20 mmHG at inclu-
sion and 134  31 and 79  23 mmHg at the end of the
study. More than 56% of the subjects obtained a satis-
factory control of BP (SBP  140 and DBP  90) and
27.4% of the patients reached an optimal control (SBP 
135 and DBP  85). The average monthly cost of hyper-
tension care per-patient over the follow-up period was
47.2€. Drugs represent the largest part of costs (30.0€,
63%), followed by physician’s visits (8.9€, 19%) diag-
nostics (3.2€, 7%), hospitalization (2.7€, 5%) and lab
tests (2.4€, 5%). CONCLUSIONS: During the observa-
tion period the majority of patients reached a satisfactory
control of BP. Drugs costs represent the most relevant
cost item among health care cost, probably due to the
time horizon of this study (on average seven months).
